title: Establishment and characterization of a pancreatic carcinoma cell line derived from malignant pleural effusion.
abstract: OBJECTIVE
  A novel cell line, designated p34, was developed from the malignant pleural effusion of a patient with carcinoma of pancreas. The objective of this work was to characterize this cell line.
  
  
  METHODS
  The in vitro studies included karyotype analysis, immunohistochemistry, XTT cell proliferation assay, analysis of the cell cycle by FACS and cell sensitivity to chemotherapeutic drugs and irradiation. Subcutaneous and intra-spleen inoculations into nude mice were carried out to study the tumorigenicity and the metastatic tendency of this cell line.
  
  
  RESULTS
  The p34 cell line showed typical morphological characteristics of epithelial pancreatic tumor cells. The cells were hyperdiploid with a modal number of 48, and had two markers, deletion in the short arm of chromosome 2 and duplication of the short arm of chromosome 8. The doubling time was 16 h. Subcutaneous inoculation of the cells into nude mice yielded 100% tumorigenicity, and intra-spleen inoculation resulted in extensive intra-abdominal spread. The antiproliferative effect of chemotherapy (gemcitabine, cisplatin, taxol and vinorelbine), chemopreventive agents (celecoxib and curcumin) and radiotherapy showed dose-dependent cytotoxicity.
  
  
  CONCLUSIONS
  This p34 cell line can be used as a new model for studying various aspects of the biology of human pancreatic cancer and potential treatment approaches for the disease.
authors.affiliation: Lung and Allergy, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: A N
authors.initials: AN
authors.lastname: Starr
authors.forename: A
authors.initials: A
authors.lastname: Vexler
authors.forename: S
authors.initials: S
authors.lastname: Marmor
authors.forename: D
authors.initials: D
authors.lastname: Konik
authors.forename: M
authors.initials: M
authors.lastname: Ashkenasi-Voghera
authors.forename: S
authors.initials: S
authors.lastname: Lev-Ari
authors.forename: Y
authors.initials: Y
authors.lastname: Greif
authors.forename: R
authors.initials: R
authors.lastname: Ben-Yosef
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy / Q000556:secondary*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D015197:Carcinogenicity Tests; D002453:Cell Cycle; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003124:Colorimetry; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007202:Indicators and Reagents; D007621:Karyotyping; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D016066:Pleural Effusion, Malignant / Q000473:pathology*; D011003:Ploidies; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D013778:Tetrazolium Salts; D014183:Transplantation, Heterologous
chemical_list: D000970:Antineoplastic Agents; D007202:Indicators and Reagents; D013778:Tetrazolium Salts; C059087:2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide